PALVELLA THERAPEUTICS, INC. - 8-K Filing
Palvella Therapeutics announces third QTORIN™ platform candidate, QTORIN™ Docetaxel, for the treatment of Extramammary Paget’s disease. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $PVLA